PATENT CLAIM ANALYSIS

Application Number: 16271689
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Claim (Index 1):
A method of treating hemophilia B comprising intravenously administering to a human subject in need thereof multiple doses of about 50 IU/kg to about 100 IU/kg of a chimeric factor IX (\u201cFIX\u201d) polypeptide comprising human FIX having an amino acid sequence identical to amino acids 1 to 415 of SEQ ID NO:2 and an FcRn binding partner (\u201cFcRn BP\u201d) at a dosing interval of about 10 days to about 14 days between two doses, wherein the FcRn BP is human Fc or human albumin, wherein the administration treats the human subject by reducing the frequency of spontaneous bleeding.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 2.13636
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16271686', '15043457', '14982934', '15890284', '13809276']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7796412087149595
- 35 USC 102 Novelty (BERT): 0.7117367205550528
- Combined Prediction Score: 0.7728507598989688
- Mean Citation Score: 881.1502200000001
- Max Citation Score: 891.02734
- Similarity Product: 735.9489942672789

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test